GlassScriptPhysician profile
Kimberlee Austin
NPI 1265485650
$1,992.71
in general payments reported to CMS, 2019-2025
28 companies · $335 in 2025
The $335 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $404 · 2020: $432 · 2021: $351 · 2022: $126 · 2023: $200 · 2024: $145 · 2025: $335.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $667 · Education: $13.35.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $666.87 |
| Education | $13.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celularity INC. | $650.00 | 2020-2021 | |
| Astellas Pharma US INC | $172.27 | 2024-2025 | Veozah |
| Mayne Pharma Commercial LLC | $133.24 | 2022-2025 | |
| Abbvie INC. | $128.03 | 2019-2022 | |
| Exeltis, USA INC. | $113.50 | 2019-2025 | Slynd |
| Therapeuticsmd, INC. | $94.01 | 2019-2022 | |
| Organon LLC | $86.30 | 2023-2025 | Nexplanon, Jada System |
| Bayer Healthcare Pharmaceuticals INC. | $82.60 | 2019-2025 | |
| Allergan, INC. | $80.67 | 2019 | |
| Avion Pharmaceuticals | $72.54 | 2019-2021 | |
| Pfizer INC. | $66.58 | 2024-2025 | |
| Coopersurgical, INC. | $30.17 | 2019 | |
| Amgen INC. | $28.18 | 2019-2025 | Prolia, Evenity |
| Millicent US INC | $27.30 | 2020-2023 | Femring |
| Vertical Pharmaceuticals, LLC | $24.97 | 2019-2020 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $24.34 | 2025 | The Cologuard Plus Collection Kit |
| Mimedx Group, INC. | $20.82 | 2025 | |
| Dysis Medical, INC. | $19.79 | 2022 | |
| Sage Therapeutics, LLC | $19.04 | 2024 | |
| Heartflow, INC. | $17.37 | 2025 | |
| Sumitomo Pharma America, INC. | $17.00 | 2023 | Myfembree |
| Sanofi Pasteur INC. | $15.24 | 2025 | |
| Pacira Pharmaceuticals Incorporated | $15.16 | 2023 | Exparel |
| Agile Therapeutics, INC. | $15.00 | 2022 | |
| Evofem Biosciences, INC. | $14.99 | 2023 | Phexxi |
| Duchesnay USA Incorporated | $12.12 | 2020 | |
| Amag Pharmaceuticals, INC. | $11.48 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$5.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kimberlee Austin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.